<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509012</url>
  </required_header>
  <id_info>
    <org_study_id>D933BC00001</org_study_id>
    <nct_id>NCT03509012</nct_id>
  </id_info>
  <brief_title>Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors</brief_title>
  <acronym>CLOVER</acronym>
  <official_title>A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of
      durvalumab Â± tremelimumab in combination with chemoradiation in patients with advanced solid
      tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will initially treat up to approximately 300 patients with advanced solid tumors
      at approximately 30 sites, worldwide. The study will be composed of a dose-limiting toxicity
      (DLT) assessment phase (Part A) and an expansion phase (Part B).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Anticipated">April 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>From the time of the first dose of durvalumab until 28 days after completion of radiation therapy</time_frame>
    <description>A DLT is defined as the occurrence of a severe AE (specified per protocol) that is at least possibly related to durvalumab or tremelimumab. AEs will be graded according to the National Cancer Institute (NCI CTCAE) version 4.03.
Collected only for Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Adverse Events (AEs)</measure>
    <time_frame>From baseline up to 90 days after the last dose of study treatment</time_frame>
    <description>AEs will be graded according to the National Cancer Institute (NCI CTCAE) version 4.03.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 12 months (PFS12)</measure>
    <time_frame>From baseline until the date of objective disease progression or death, whichever came first, at 12 months.</time_frame>
    <description>Defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by the Investigator).
NSCLC and SCLC cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the date of the first dose until death due to any cause, through study completion, up to 4 years.</time_frame>
    <description>Defined as the time from the date of first dose until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.
NSCLC and SCLC cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From baseline up until disease progression, or the last evaluable assessment (RECIST 1.1) in the absence of progression, assessed through study completion, up to 4 years.</time_frame>
    <description>Number (%) of patients with an overall response of complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best objective response (BoR)</measure>
    <time_frame>From baseline until disease progression, follow up assessments (RECIST 1.1) starts at week 16 (post first dose of durvalumab) and continue every 8 weeks until week 48 and after every 12 weeks, assessed through study completion, up to 4 years.</time_frame>
    <description>The best response based on the overall visit responses from each RECIST 1.1 assessment or the last evaluable assessment in the absence of RECIST 1.1 progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>From baseline until disease progression, follow up assessments (RECIST 1.1) starts at week 16 (post first dose of durvalumab) and continue every 8 weeks until week 48 and after every 12 weeks, assessed through study completion, up to 4 years.</time_frame>
    <description>Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression.
(NSCLC and SCLC cohorts only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From baseline until disease progression, follow up assessments (RECIST 1.1) starts at week 16 (post first dose of durvalumab) and continue every 8 weeks until week 48, assessed through study completion, up to 4 years.</time_frame>
    <description>The percentage of patients who have a BoR of CR or PR in the first 12 or 48 weeks, respectively, or who have demonstrated stable disease (SD) for a minimum interval of 12 or 48 weeks, respectively following the start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>From baseline until disease progression, follow up assessments (RECIST 1.1) starts at week 16 (post first dose of durvalumab) and continue every 8 weeks until week 48 and after every 12 weeks, assessed through study completion, up to 4 years.</time_frame>
    <description>Kaplan-Meier estimate of disease-free survival. (HNSCC cohort only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 18 months (PFS18)</measure>
    <time_frame>From baseline until the date of objective disease progression or death, whichever came first, at 18 months.</time_frame>
    <description>Defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by the Investigator).
NSCLC and SCLC cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival at 48 weeks (DFS48)</measure>
    <time_frame>From baseline until disease progression or death, whichever came first at 48 weeks.</time_frame>
    <description>Kaplan-Meier estimate of disease-free survival. (HNSCC cohort only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival at 96 weeks (DFS96)</measure>
    <time_frame>From baseline until disease progression or death, whichever came first at 96 weeks.</time_frame>
    <description>Kaplan-Meier estimate of disease-free survival. (HNSCC cohort only)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>HNSCC Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCLC Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>IV (intravenous)</description>
    <arm_group_label>HNSCC Arm 1</arm_group_label>
    <arm_group_label>NSCLC Arm 1</arm_group_label>
    <arm_group_label>NSCLC Arm 2</arm_group_label>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>IV</description>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (dose level 4)</intervention_name>
    <description>IV</description>
    <arm_group_label>HNSCC Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (dose level 3)</intervention_name>
    <description>IV</description>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin (dose level 1)</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin (dose level 2)</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide (dose level 1)</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide (dose level 2)</intervention_name>
    <description>IV</description>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation (dose level 1)</intervention_name>
    <description>radiation therapy</description>
    <arm_group_label>HNSCC Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation (dose level 2)</intervention_name>
    <description>radiation therapy</description>
    <arm_group_label>NSCLC Arm 1</arm_group_label>
    <arm_group_label>NSCLC Arm 2</arm_group_label>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation (hyperfractionated)</intervention_name>
    <description>radiation therapy</description>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (dose level 1)</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (dose level 2)</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation (standard)</intervention_name>
    <description>radiation therapy</description>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_label>SCLC Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  World Health Organization (WHO)/ECOG performance status of 0 or 1

          -  Body weight &gt;30 kg at enrollment and treatment assignment

          -  At least 1 measurable lesion, not previously irradiated

          -  No prior exposure to immune-mediated therapy (including therapeutic anticancer
             vaccines)

          -  For patients with oropharyngeal HNSCC HPV status has to be known

        Exclusion criteria:

          -  Patients with simultaneous primary malignancies or bilateral tumors

          -  Active or prior documented autoimmune or inflammatory disorders

          -  Brain metastases or spinal cord compression

          -  Active infection including tuberculosis, hepatitis B, hepatitis C, or human
             immunodeficiency virus (HIV; positive HIV 1/2 antibodies)

          -  Has a paraneoplastic syndrome (PNS) of autoimmune nature

          -  HNSCC cohort: Head and neck cancer that does not include unresectable, locally
             advanced cancer of oral cavity, larynx, oropharynx or hypopharynx. HNSCC of unknown
             primary are also excluded

          -  NSCLC and SCLC cohort: Mixed SCLC and NSCLC histology

          -  SCLC cohort: Extensive-stage SCLC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Durvalumab</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>HNSCC</keyword>
  <keyword>NSCLC</keyword>
  <keyword>SCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

